Skip to content Skip to footer
Subscribe Now
Telix Pharmaceuticals
NEWS

Telix Pharmaceuticals Reports Preliminary P-II (IPAX-Linz) Trial Data of TLX101 to Treat Glioma

Shots:The IIT P-II (IPAX-Linz) trial assessed TLX101 (IV) in 8 glioblastoma pts with recurrent tumors & PET-confirmed amino acid uptake, who received adaptive dosing with ~4GBq before & ~2GBq after, 2L EBRT; 5/8 had MGMT-unmethylated tumorsTrial showed mOS of 12.4mos. or 32.2mos. from initial diagnosis, complementing P-I (IPAX-1) trial results of 13mos. & 23mos.,…
April 17, 2025

Read more

Disease of the Month - Neuroblastoma
INSIGHTS+

Disease of the Month – Neuroblastoma

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved  For the February edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Neuroblastoma, a rare…
February 13, 2024

Read more

Disease of the Month - Glioblastoma
INSIGHTS+

Disease of the Month – Glioblastoma

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…
January 11, 2024

Read more

New Drug Designations - October 2023
INSIGHTS+

New Drug Designations – October 2023

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA and the EMA. This month’s report includes 2 biological drugs, 12 small molecules, 10 cell and gene therapies, 2 vaccines, 1 peptide, 1 exosome-based therapy and 3 devices HuidaGene Therapeutics’ HG204 CRISPR RNA-editing therapy, focused on the treatment of MECP2 duplication…
November 20, 2023

Read more

New Drug Designations - August 2023
INSIGHTS+

New Drug Designations – August 2023

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, Japan, and China. This month’s report includes 8 biological drugs, 13 small molecules, 4 cell and gene therapies, 3 diagnostic tests and 5 devices Genprex’ Reqorsa, focused on the treatment of SCLC, is the drug to receive ODD…
September 18, 2023

Read more

ViewPoint_William_F_Doyle_2020
VIEWPOINTS

PharmaShots Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company's activities in the field of glioblastoma and mesothelioma. He also discussed the company's technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors.Shots:Novocure is a global oncology company working to extend survival…
December 9, 2020

Read more